Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ALLEGRA HIVES versus CHILDREN S CETIRIZINE HYDROCHLORIDE ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ALLEGRA HIVES versus CHILDREN S CETIRIZINE HYDROCHLORIDE ALLERGY.
CHILDREN'S ALLEGRA HIVES vs CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine-mediated effects, reducing pruritus and urticaria.
Cetirizine is a selective antagonist of peripheral histamine H1 receptors. It inhibits the H1 receptor-mediated effects of histamine, reducing symptoms such as pruritus, sneezing, rhinorrhea, and urticaria. It also decreases eosinophil chemotaxis and adhesion molecule expression.
Fexofenadine 180 mg orally once daily for adults and children 12 years and older.
5-10 mg orally once daily; max 10 mg/day. For children's formulation, typical adult dose applies to patients >12 years.
None Documented
None Documented
Terminal half-life: 14.4 hours; clinical context: supports twice-daily dosing in chronic urticaria
Approximately 8.3 hours (range 6–10 hours) in healthy adults; prolonged in renal impairment (e.g., up to 20 hours).
Fecal (80% as unchanged drug); renal (15%, mostly as metabolites; <5% unchanged)
Renal: ~60% unchanged; fecal: ~10%; minor biliary elimination.
Category C
Category A/B
Antihistamine
Antihistamine